SGLT2 is a sodium-dependent glucose transporter protein located in the proximal tubules of the kidneys, responsible for reabsorbing approximately 90% of the filtered glucose by the kidney.1 The increased filtered glucose to the kidneys in patients with type 2 diabetes causes an increased expression of SGLT2 protein in the proximal tubules, thereby resulting in increased glucose reabsorption and hyperglycemia.2,3 SGLT2 inhibitors improve glycemic control by reversible inhibition of SGLT2, resulting in decreased glucose reabsorption and increased glucose excretion in urine. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.